Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-_xL

References

• Chatenoud L, Bertuccio P, Bosetti C, . Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007. Cancer 2010;116:5063–5074.
   Google Scholar
• Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277–285.
   PubMed Web of Science ®Google Scholar
• Sandlund JT, Pui CH, Mahmoud H, . Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol 2011;22:468–471.
   PubMed Web of Science ®Google Scholar
• Laver JH, Kraveka JM, Hutchison RE, . Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005;23:541–547.
   PubMed Web of Science ®Google Scholar
• Soltani-Arabshahi R, Leboeuf C, Rivet J, . Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J Invest Dermatol 2009;129:1703–1709.
   PubMed Web of Science ®Google Scholar
• Zhao WL, Daneshpouy ME, Mounier N, . Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004;103:695–697.
   PubMed Web of Science ®Google Scholar
• Lebedeva I, Rando R, Ojwang J, . Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000;60:6052–6060.
   PubMed Web of Science ®Google Scholar
• Villedieu M, Louis MH, Dutoit S, . Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007;105:31–44.
   PubMed Web of Science ®Google Scholar
• Wang R, Lin F, Wang X, . Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells. Cancer Chemother Pharmacol 2008;61:943–952.
   PubMed Web of Science ®Google Scholar
• Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999; 274:13298–13304.
   PubMed Web of Science ®Google Scholar
• Arnold AA, Aboukameel A, Chen J, . Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008;7:20.
   PubMed Web of Science ®Google Scholar
• Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687–2695.
   PubMed Web of Science ®Google Scholar
• Vega MI, Jazirehi AR, Huerta-Yepez S, . Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005;175:2174–2183.
   PubMed Web of Science ®Google Scholar
• Chen N, Chen X, Huang R, . BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 2009;284: 10004–10012.
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Escuin D, LaVallee TM, . 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363–375.
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011;14:191–201.
   PubMed Web of Science ®Google Scholar
• Evens AM, Sehn LH, Farinha P, . Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28:1017–1024.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Pezzella F, . Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008;26:219–224.
   PubMed Web of Science ®Google Scholar
• Li B, Takeda K, Yokoyama S, . A prolyl-hydroxylase inhibitor, ethyl-3,4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. J Biochem 2008;144:643–654.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H. 2-Methoxyestradiol–biology and mechanism of action. Steroids 2010;75:625–631.
   PubMed Web of Science ®Google Scholar
• Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000;65:95–106.
   PubMed Web of Science ®Google Scholar
• Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989–1000.
   PubMed Web of Science ®Google Scholar
• Amundson SA, Myers TG, Scudiero D, . An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101–6110.
   PubMed Web of Science ®Google Scholar
• Qiao Q, Nozaki Y, Sakoe K, . NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol 2010;38:1199–1208.
   PubMed Web of Science ®Google Scholar
• Evens AM, Schumacker PT, Helenowski IB, . Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008;141: 676–680.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001;20:5779–5788.
   PubMed Web of Science ®Google Scholar
• Graeber TG, Osmanian C, Jacks T, . Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91.
   PubMed Web of Science ®Google Scholar
• Park SS, Kim MA, Eom YW, . Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe. Biochem Biophys Res Commun 2007;363:1044–1049.
   PubMed Web of Science ®Google Scholar
• Park J, Franco RS, Augsburger JJ, . Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma. Curr Eye Res 2007;32:659–667.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Chatterjee D, . Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 2004;64:7117–7126.
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673–683.
   PubMed Web of Science ®Google Scholar
• Bu S, Blaukat A, Fu X, . Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002; 531:141–151.
   PubMed Web of Science ®Google Scholar
• Attalla H, Westberg JA, Andersson LC, . 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998;247:616–619.
   PubMed Web of Science ®Google Scholar
• Joubert A, Maritz C, Joubert F. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res 2005;26:131–134.
   PubMed Web of Science ®Google Scholar
• Piret JP, Minet E, Cosse JP, . Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 2005;280:9336–9344.
   PubMed Web of Science ®Google Scholar
• Gao N, Rahmani M, Dent P, . 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005;24:3797–3809.
   PubMed Web of Science ®Google Scholar
• Zhong H, Chiles K, Feldser D, . Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541–1545.
   PubMed Web of Science ®Google Scholar
• Iqbal S, Zhang S, Driss A, . PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. PLoS One 2012;7:e30764.
   PubMed Web of Science ®Google Scholar
• Lee KB, Byun HJ, Park SH, . CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 2012;315:86–95.
   PubMed Web of Science ®Google Scholar